<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2019.81007</article-id><article-id pub-id-type="publisher-id">HJO-29401</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20190100000_72408033.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  OCTA在雷珠单抗治疗慢性中心性浆液性脉络膜视网膜病变合并CNV的临床应用
  Role of Optical Coherence Tomography Angiography in Chronic Central Serous Chorioretinopathy with CNV after Intravitreal Injections of Ranibizumab
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>国奇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>鲍</surname><given-names>炯琳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>臧</surname><given-names>晶</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>姚</surname><given-names>翠群</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>广东药科大学附属第一医院连南医院(连南瑶族自治县人民医院)，广东 连南</addr-line></aff><aff id="aff3"><addr-line>广东药科大学附属第一医院，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>01</month><year>2019</year></pub-date><volume>08</volume><issue>01</issue><fpage>33</fpage><lpage>40</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：在OCTA指导下观察玻璃体腔注射雷珠单抗治疗慢性中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC)合并CNV的临床疗效。方法：选取2016/07~2018/03我院确诊的9例9眼慢性CSC合并CNV的患者，按照“3 + PRN”方案给予玻璃体腔注射0.5 mg/0.05 mL雷珠单抗治疗。治疗后每月随访病情，随访时间为6 mo，观察指标包括治疗前后的最佳矫正视力(best-corrected visual acuity, BCVA)、眼压以及通过光学相干断层扫描血管成像(optical coherence tomography angiography, OCTA)观察的黄斑中心凹厚度(central macular thinkness, CMT)和脉络膜新生血管(choroidal neovascularization, CNV)的面积。结果：患者9例9眼中，雷珠单抗玻璃体腔注药前9眼患者CMT平均值为373.12 &#177; 72.43 μm，雷珠单抗治疗后1 w、1 mo、3 mo、6 mo时CMT分别为346.42 &#177; 65.32、332.05 &#177; 67.13、282.24 &#177; 62.30、225.56 &#177; 71.08 μm，与治疗前相比均具有统计学差异(P &lt; 0.05)。玻璃体腔注药前9眼患者CNV面积平均值为1.13 &#177; 0.23 mm2，治疗后1 w、1 mo、3 mo、6 mo时CNV面积平均值分别为1.05 &#177; 0.32、0.85 &#177; 0.13、0.65 &#177; 0.30、0.65 &#177; 0.25 mm2，与治疗前相比均具有统计学差异(P &lt; 0.05)。治疗前BCVA为0.30&#177;0.12，注射后1 w、1 mo、3 mo、6 mo的BCVA分别为0.43 &#177; 0.21、0.45 &#177; 0.15、0.50 &#177; 0.06、0.55 &#177; 0.20，与治疗前相比均具有统计学差异(P &lt; 0.05)。结论：玻璃体腔注射雷珠单抗治疗慢性CSC合并CNV疗效显著、安全性高；患者玻璃体腔注射雷珠单抗可以有效促进视网膜下液的吸收，降低CMT，可以促进CNV的吸收消退，提高视力。OCTA能无创、快速获得视网膜和脉络膜血管图像，为诊断慢性CSC合并CNV和监控其治疗效果提供有力证据。
   AIM: To observe the clinical efficacy of intravitreal injection of ranibizumab in the treatment of chronic central serous chorioretinopathy (CSC) with CNV under the guidance of OCTA. Methods: Nine patients with 9 eyes with chronic CSC and CNV diagnosed in our hospital from 2016/07 to 2018/03 were treated with intravitreal injection of 0.5 mg/0.05 mL of ranibizumab. The patients were followed up every month for 6 months after treatment. The observed indicators included best-corrected visual acuity (BCVA), intraocular pressure, central macular thickness (CMT), and choroidal neovascularization (CNV) area by optical coherence tomography angiography (OCTA). Results: In 9 eyes of 9 patients, the average CMT of 9 eyes before injection in the vitreous cavity was 373.12 &#177; 72.43 μm, and the CMT at 1 w, 1 mo, 3 mo and 6 mo after treatment with razurizumab was 346.42 &#177; 65.32, 332.05 &#177; 67.13, 282.24 &#177; 62.30, 225.56 &#177; 71.08 μm. There was a statistical difference (P &lt; 0.05) compared with that before treatment. The average CNV area of the 9 eyes before injection in the vitreous cavity was 1.13&#177; 0.23 mm2. The average CNV area at 1 w, 1 mo, 3 mo and 6 mo after treatment was 1.05 &#177; 0.32, 0.85 &#177; 0.13, 0.65 &#177; 0.30, 0.65 &#177; 0.25 mm2, respectively. There was a statistical difference (P &lt; 0.05) compared with before treatment. The BCVA before treatment was 0.30 &#177; 0.12, and the BCVA at 1 w, 1 mo, 3 mo and 6 mo after injection were 0.43 &#177; 0.21, 0.45 &#177; 0.15, 0.50 &#177; 0.06 and 0.55 &#177; 0.20, respectively, which were statistically different compared with before treatment (P &lt; 0.05). Conclusion: Intravitreal injection of ranibizumab in the treatment of chronic CSC combined with CNV has a significant and safe effect; the patient’s intravitreal injection of ranibizumab can effectively promote the absorption of subretinal fluid, reduce CMT, can promote the absorption of CNV, and improve vision. OCTA provides non-invasive, rapid acquisition of retinal and choroidal blood vessel images, providing strong evidence for the diagnosis of chronic CSC with CNV and monitoring of its therapeutic effects.
 
</p></abstract><kwd-group><kwd>OCTA，慢性中心性浆液性脉络膜视网膜病变，脉络膜新生血管，雷珠单抗, OCTA</kwd><kwd> Chronic Central Serous Chorioretinopathy</kwd><kwd> Choroidal Neovascularization</kwd><kwd> Ranibizumab</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>OCTA在雷珠单抗治疗慢性中心性浆液性脉络膜视网膜病变合并CNV的临床应用<sup> </sup></title><p>管国奇<sup>1</sup>，鲍炯琳<sup>2*</sup>，臧晶<sup>2</sup>，姚翠群<sup>2</sup></p><p><sup>1</sup>广东药科大学附属第一医院连南医院(连南瑶族自治县人民医院)，广东 连南</p><p><sup>2</sup>广东药科大学附属第一医院，广东 广州</p><disp-formula id="hanspub.29401-formula50"><graphic xlink:href="//html.hanspub.org/file/7-2230223x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年2月28日；录用日期：2019年3月18日；发布日期：2019年3月25日</p><disp-formula id="hanspub.29401-formula51"><graphic xlink:href="//html.hanspub.org/file/7-2230223x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：在OCTA指导下观察玻璃体腔注射雷珠单抗治疗慢性中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC)合并CNV的临床疗效。方法：选取2016/07~2018/03我院确诊的9例9眼慢性CSC合并CNV的患者，按照“3 + PRN”方案给予玻璃体腔注射0.5 mg/0.05 mL雷珠单抗治疗。治疗后每月随访病情，随访时间为6 mo，观察指标包括治疗前后的最佳矫正视力(best-corrected visual acuity, BCVA)、眼压以及通过光学相干断层扫描血管成像(optical coherence tomography angiography, OCTA)观察的黄斑中心凹厚度(central macular thinkness, CMT)和脉络膜新生血管(choroidal neovascularization, CNV)的面积。结果：患者9例9眼中，雷珠单抗玻璃体腔注药前9眼患者CMT平均值为373.12 &#177; 72.43 μm，雷珠单抗治疗后1 w、1 mo、3 mo、6 mo时CMT分别为346.42 &#177; 65.32、332.05 &#177; 67.13、282.24 &#177; 62.30、225.56 &#177; 71.08 μm，与治疗前相比均具有统计学差异(P &lt; 0.05)。玻璃体腔注药前9眼患者CNV面积平均值为1.13 &#177; 0.23 mm<sup>2</sup>，治疗后1 w、1 mo、3 mo、6 mo时CNV面积平均值分别为1.05 &#177; 0.32、0.85 &#177; 0.13、0.65 &#177; 0.30、0.65 &#177; 0.25 mm<sup>2</sup>，与治疗前相比均具有统计学差异(P &lt; 0.05)。治疗前BCVA为0.30&#177;0.12，注射后1 w、1 mo、3 mo、6 mo的BCVA分别为0.43 &#177; 0.21、0.45 &#177; 0.15、0.50 &#177; 0.06、0.55 &#177; 0.20，与治疗前相比均具有统计学差异(P &lt; 0.05)。结论：玻璃体腔注射雷珠单抗治疗慢性CSC合并CNV疗效显著、安全性高；患者玻璃体腔注射雷珠单抗可以有效促进视网膜下液的吸收，降低CMT，可以促进CNV的吸收消退，提高视力。OCTA能无创、快速获得视网膜和脉络膜血管图像，为诊断慢性CSC合并CNV和监控其治疗效果提供有力证据。</p><p>关键词 :OCTA，慢性中心性浆液性脉络膜视网膜病变，脉络膜新生血管，雷珠单抗</p><disp-formula id="hanspub.29401-formula52"><graphic xlink:href="//html.hanspub.org/file/7-2230223x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/7-2230223x8_hanspub.png" /> <img src="//html.hanspub.org/file/7-2230223x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>中心性浆液性视网膜脉络膜病变(central serous chorioretinopathy, CSC)作为一种黄斑疾病，其特征是视网膜下积液，这种积液经常影响黄斑，随后中心视力丧失，生活质量下降 [<xref ref-type="bibr" rid="hanspub.29401-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref2">2</xref>] 。CSC通常为自限性，但部分患者可复发，迁延不愈转变为慢性CSC，从而对视力造成永久性损伤 [<xref ref-type="bibr" rid="hanspub.29401-ref3">3</xref>] 。脉络膜新生血管(choroidal neovascularization, CNV)是一种相对少见的慢性CSC并发症，发病率估计在2%至9%之间 [<xref ref-type="bibr" rid="hanspub.29401-ref4">4</xref>] 。此外，CNV可能是慢性CSC视力下降的主要原因 [<xref ref-type="bibr" rid="hanspub.29401-ref4">4</xref>] 。虽然CSC可以保守治疗，但CNV的发展可能需要及时的抗血管内皮生长因子治疗 [<xref ref-type="bibr" rid="hanspub.29401-ref5">5</xref>] 。本研究对慢性CSC继发CNV的患者接受玻璃体腔注射雷珠单抗的治疗进行6 mo疗效观察，现将结果报告如下。</p></sec><sec id="s4"><title>2. 资料与方法</title><p>一般资料将2016/07~2018/03在广东药科大学附属第一医院眼科确诊为慢性CSC的9例9眼患者纳入本研究。其中男7眼，女2眼，男女比例为7:2。患者年龄为41~65 (平均48.67 &#177; 7.40)岁。病程持续时间为6~32 (平均18.41 &#177; 5.52) mo。视力0.02~0.6，平均0.3。纳入及排除标准：1) OCTA检查可见视网膜神经上皮层或合并RPE层浆液性脱离以及CNV；2) FFA检查可见黄斑部视网膜荧光渗漏点；3) ICGA检查可见病变区脉络膜血管扩张，晚期高荧光；4) 病程 ≥ 6 mo；5) 双眼均无黄斑区的其他病变，之前未做过任何治疗；6) 50岁以上患者，通过ICGA排除息肉状脉络膜血管病变。本研究经院伦理委员会同意，所有对象均知晓本次研究，并已签署知情同意书(见图1)。</p><p>图1. 慢性CSC合并CNV</p><sec id="s4_1"><title>2.1. 方法</title><p>患者9例9眼，按照“3 + PRN”方案行玻璃体腔内注射雷珠单抗0.05 ml，其中2眼患者在第5月再次给予相同剂量的玻璃体腔注射。分别于注射前和注射后1 w、1 mo、3 mo、6 mo对所有患者进行随访。所有患者治疗前均行BCVA、间接检眼镜、OCTA、FFA及ICGA检查。随诊时行BCVA、间接检眼镜、OCTA检查。OCTA测量的项目为黄斑中心凹厚度(central macular thickness, CMT)和CNV面积。CMT和CNV面积，均由同一位有经验的眼科医生独立完成，分别测量3次，取平均值作为最终数据。</p></sec><sec id="s4_2"><title>2.2. 统计学分析</title><p>采用SPSS 20.0 统计学软件，治疗前后患者临床指标以x &#177; s表示，对治疗前后的BCVA、CMT和CNV面积比较采用重复测量数据的方差分析。治疗后不同时间点BCVA、CMT和CNV面积与治疗前比较采用LSD-t检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 治疗前后患者BCVA的变化</title><p>治疗前及治疗后不同时间点患者的BCVA(logMAR视力)变化见表1。治疗后1 w、1 mo、3 mo、6 mo患者BCVA与治疗前比较，差异均有统计学意义(P = 0.040, 0.013, 0.016, 0.016)。治疗后1 mo、3 mo、6 mo患者BCVA与治疗后1w比较，差异均有统计学意义(P = 0.014, 0.007, 0.007)；治疗后3 mo、6 mo患者BCVA与治疗后1 mo比较，差异有统计学意义(P = 0.018, 0.017)；治疗后6 mo患者BCVA与治疗后3 mo比较，差异无统计学意义(P = 0.956)。</p></sec><sec id="s5_2"><title>3.2. 治疗前后CMT的变化</title><p>治疗前及治疗后不同时间点患者的CMT值变化见表1。与治疗前比较，患者接受治疗后1 w、1 mo、3 mo、6 mo的CMT均显著下降，差异均有统计学意义(P = 0.008, 0.002, 0.005, 0.005)。治疗后1 mo、3 mo、6 mo患者的CMT与治疗后1w比较，差异均有统计学意义(P = 0.004, 0.005, 0.005)；治疗后3 mo、6 mo患者CMT与治疗后1 mo比较，差异均无统计学意义(P = 0.350, 0.762)；治疗后6 mo患者CMT与治疗后3 mo比较，差异无统计学意义(P = 0.523)。</p></sec><sec id="s5_3"><title>3.3. 治疗前后CNV面积的变化</title><p>治疗前及治疗后不同时间点患者的CNV面积变化见表1及图2。与治疗前比较，患者接受治疗后7眼患者1 w、1 mo、3 mo、6 mo的CNV面积均显著下降，差异均有统计学意义(P = 0.010, 0.007, 0.015, 0.012)。治疗后1 mo、3 mo、6 mo患者的CNV面积与治疗后1w比较，差异均有统计学意义(P = 0.006, 0.011、0.008)；治疗后3 mo、6 mo患者CNV面积与治疗后1 mo比较，差异有统计学意义(P = 0.010, 0.012)；治疗后6 mo患者CNV面积与治疗后3 mo比较，差异无统计学意义(P = 0.628)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of BCVA, CMT and CNV before and after injection in patients with CS</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后1 w</th><th align="center" valign="middle" >治疗后1 mo</th><th align="center" valign="middle" >治疗后3 mo</th><th align="center" valign="middle" >治疗后6 mo</th></tr></thead><tr><td align="center" valign="middle" >BCVA</td><td align="center" valign="middle" >0.30 &#177; 0.12</td><td align="center" valign="middle" >0.43 &#177; 0.21</td><td align="center" valign="middle" >0.45 &#177; 0.15</td><td align="center" valign="middle" >0.50 &#177; 0.06</td><td align="center" valign="middle" >0.55 &#177; 0.20</td></tr><tr><td align="center" valign="middle" >CMT/μm</td><td align="center" valign="middle" >373.12 &#177; 72.43</td><td align="center" valign="middle" >346.42 &#177; 65.32</td><td align="center" valign="middle" >332.05 &#177; 67.13</td><td align="center" valign="middle" >282.24 &#177; 62.30</td><td align="center" valign="middle" >225.56 &#177; 71.08</td></tr><tr><td align="center" valign="middle" >CNV面积/mm<sup>2</sup></td><td align="center" valign="middle" >1.13 &#177; 0.23</td><td align="center" valign="middle" >1.05 &#177; 0.32</td><td align="center" valign="middle" >0.85 &#177; 0.13</td><td align="center" valign="middle" >0.65 &#177; 0.30</td><td align="center" valign="middle" >0.65 &#177; 0.25</td></tr></tbody></table></table-wrap><p>表1. 慢性CSC患者注药前后BCVA、CMT和CNV面积的比较</p><p>图2. 玻璃体腔注射雷珠单抗前后CNV的Angio OCT变化</p></sec><sec id="s5_4"><title>3.4. 并发症</title><p>随访期间所有患者均未出现与治疗相关的并发症，未见全身不良反应。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>CSC具有自限性，通常是一个良性的临床过程，但其复发率高。多见于中年男性，男女发病率为(3~6)：1，而其他风险因素包括使用皮质类固醇，可能是A型人格，以及怀孕 [<xref ref-type="bibr" rid="hanspub.29401-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref7">7</xref>] 。对CSC，目前没有比较公认的分类方法，临床上常根据病程是否超过6个月将其分为急性CSC和慢性CSC [<xref ref-type="bibr" rid="hanspub.29401-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref9">9</xref>] 。慢性CSC患者病变多较严重，长期迁延不愈可继发CNV [<xref ref-type="bibr" rid="hanspub.29401-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref10">10</xref>] 。CNV虽然在慢性CSC的患者中较罕见，但可造成不可逆的视力损伤，因此对CNV的诊断及治疗就显得尤为重要。光学相干断层扫描血管成像(optical coherence tomography angiography, OCTA)作为一种新型无创性血管成像技术，能够分层显示视网膜脉络膜毛细血管网并可量化血管密度及病灶面积等，能直接观察到眼部病变范围、深度及新生血管长度、口径大小、面积等变化，具有重要的临床指导意义 [<xref ref-type="bibr" rid="hanspub.29401-ref11">11</xref>] 。此外有研究表明仍有25%的慢性CSC合并CNV的患者在FFA检查未发现CNV而在OCTA检查中发现CNV [<xref ref-type="bibr" rid="hanspub.29401-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref14">14</xref>] 。OCTA不仅可观察到新生血管的形态及血流，而且可以清晰地辨别出CNV的轮廓，OCTA可用于检测和分类CNV，并且可以定量测量新生血管面积 [<xref ref-type="bibr" rid="hanspub.29401-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.29401-ref16">16</xref>] 。慢性CSC继发CNV目前还没有治疗的金标准 [<xref ref-type="bibr" rid="hanspub.29401-ref17">17</xref>] 。由Yan [<xref ref-type="bibr" rid="hanspub.29401-ref18">18</xref>] 进行的一项前瞻性临床研究报道玻璃体内注射anti-VEGF药物(如雷珠单抗)对CSC (尤其是CSC合并CNV)能显著提高CSC患者的视力，减轻黄斑及视网膜水肿，促进玻璃体及视网膜出血的吸收，有效消退脉络膜和视网膜的新生血管，是一种安全、有效的治疗方法。这与本研究结果类似。</p><p>在本研究中，我们对9例9眼慢性CSC合并CNV的患者进行玻璃体腔内注射雷珠单抗治疗，其中有7眼患者在注药后的随访过程中，黄斑部视网膜厚度和CNV面积均进行性下降，CNV血管网直径缩小，密度降低，视网膜下液明显吸收，视力改善。这说明抗VEGF单克隆抗体雷珠单抗玻璃体注射在治疗慢性CSC合并CNV中可减轻水肿程度，减少脉络膜毛细血管的渗漏，使视功能得到恢复。2眼患者在连续3次玻璃体腔内注射雷珠单抗后CNV面积虽未明显变小，但其视网膜下液有所吸收，视力较治疗前有所改善，然后我们在第5月再次给予相同剂量的玻璃体腔注射，第6月后复查OCTA，可见CNV面积仍无明显变小，但CNV血管网直径缩小及密度降低明显，患者视力较治疗前明显提高(见图3)。由此我们认为对于慢性CSC合并CNV的患者，雷珠单抗仍然是治疗CNV的最主要方法。雷珠单抗作为一种人源化的重组单克隆抗体片段能靶向地结合VEGF-A，抑制VEGF-A与其受体结合，进而阻止内皮细胞增殖，降低血管通透性，缓解黄斑水肿，抑制CNV形成。</p><p>目前已有研究证实OCTA在监测雷珠单抗治疗CNV随访过程中具有重要意义。Mastropasqua等 [<xref ref-type="bibr" rid="hanspub.29401-ref19">19</xref>] 通过OCTA发现玻璃体腔注射1次或多次抗VEGF治疗后会影响视网膜、脉络膜表层血流密度，同时减少新生血管血流面积和中央视网膜厚度。国内也有学者用OCTA观察抗VEGF治疗CNV的疗效，发现治疗后BCVA较术前明显改善，黄斑中心视网膜厚度明显减少，并且显示CNV血管网直径缩小，密度降低 [<xref ref-type="bibr" rid="hanspub.29401-ref20">20</xref>] 。我们的研究也基本证实了这一点，我们用OCTA观察首次确诊为慢性CSC合并CNV的患者在玻璃体腔注射雷珠单抗后发现CNV面积明显减少，CNV血管网直径缩小，密度降低。因此从长期的随访结果来看，慢性CSC合并CNV的患者通过OCTA不仅仅可以明确诊断CNV，而且可以定量玻璃体腔注射雷珠单抗后CNV的吸收消退情况，可能为患者提供了一个预后的评估。</p><p>图3. 玻璃体腔注射雷珠单抗前后CNV的OCTA变化</p><p>综上所述，雷珠单抗玻璃体腔注射仍然是治疗慢性CSC合并CNV的最主要方法；雷珠单抗治疗慢性CSC合并CNV效果显著，能够促进黄斑中心凹视网膜下浆液吸收，降低黄斑中心凹视网膜厚度，促进CNV消退，同时提高视力。与此同时OCTA能无创、快速、精确地定性及定量分析视网膜结构形态改变，为诊断和监控其治疗效果提供有力证据。给临床工作者和患者提供了极大的方便。但本次研究样本数量较少，随访时间较短，结果还有待今后大样本量、长期随访观察及多中心研究结果进一步验证。</p></sec><sec id="s7"><title>文章引用</title><p>管国奇,鲍炯琳,臧 晶,姚翠群. OCTA在雷珠单抗治疗慢性中心性浆液性脉络膜视网膜病变合并CNV的临床应用Role of Optical Coherence Tomography Angiography in Chronic Central Serous Chorioretinopathy with CNV after Intravitreal Injections of Ranibizumab[J]. 眼科学, 2019, 08(01): 33-40. https://doi.org/10.12677/HJO.2019.81007</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.29401-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Breukink, M.B., Dingemans, A.J.M., den Hollander, A.I., Keunen, J.E.E., MacLaren, R.E., Fauser, S., et al. (2017) Chronic Central Serous Chorioretinopathy: Long-Term Follow-Up and Vision-Related Quality of Life. Clinical Ophthalmology, 11, 39-46. https://doi.org/10.2147/OPTH.S115685</mixed-citation></ref><ref id="hanspub.29401-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Daruich, A., Matet, A., Dirani, A., et al. (2015) Central Serous Chorioretinopathy: Recent Findings and New Physiopathology Hypothesis. Progress in Retinal and Eye Research, 48, 82-118.  
https://doi.org/10.1016/j.preteyeres.2015.05.003</mixed-citation></ref><ref id="hanspub.29401-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">姚亮, 吕莎莎, 刘子瑶, 等. 康柏西普治疗慢性中心性浆液性脉络膜视网膜病变的疗效[J]. 国际眼科杂志, 2017, 17(6): 1139-1142.</mixed-citation></ref><ref id="hanspub.29401-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Loo, R.H., Scott, I.U., Flynn Jr., H.W., et al. (2002) Factors Associated with Reduced Visual Acuity during Long-Term Follow-Up of Patients with Idiopathic Central Serous Chorioretinopathy. Retina, 22, 19-24.  
https://doi.org/10.1097/00006982-200202000-00004</mixed-citation></ref><ref id="hanspub.29401-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bonini Filho, M.A., de Carlo, T.E., Ferrara, D., et al. (2015) Associ-ation of Choroidal Neovascularization and Central Serous Chorioretinopathy with Optical Coherence Tomography Angiography. JAMA Ophthalmology, 133, 899-906.  
https://doi.org/10.1001/jamaophthalmol.2015.1320</mixed-citation></ref><ref id="hanspub.29401-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">van Rijssen, T.J., van Dijk, E.H.C., Dijkman, G., et al. (2018) Clinical Characteristics of Chronic Central Serous Chorioretinopathy Patients with Insufficient Response to Reduced-Settings Photodynamic Therapy. Graefe’s Archive for Clinical and Experimental Ophthalmology, 256, 1395-1402. https://doi.org/10.1007/s00417-018-4003-z</mixed-citation></ref><ref id="hanspub.29401-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">吴敏, 胡竹林, 薛黎萍, 李云琴, 肖丽波. 半剂量维替泊芬和半能量PDT治疗慢性中心性浆液性脉络膜视网膜病变[J]. 眼科新进展, 2015, 35(7): 646-648.</mixed-citation></ref><ref id="hanspub.29401-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yang, D. and Eliott, D. (2017) Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Seminars in Ophthalmology, 32, 36-42. https://doi.org/10.1080/08820538.2016.1228418</mixed-citation></ref><ref id="hanspub.29401-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sugiura, A., Fujino, R., Takemiya, N., et al. (2017) The Association between Visual Function and Retinal Structure in Chronic Central Serous Chorioretinopathy. Scientific Reports, 7, Article Number: 16288.  
https://doi.org/10.1038/s41598-017-16339-9</mixed-citation></ref><ref id="hanspub.29401-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Bujarborua, D. (2001) Long-Term Follow-Up of Idiopathic Central Serous Chorioretinopathy without Laser. Acta Ophthalmologica Scandinavica, 79, 417-421. https://doi.org/10.1034/j.1600-0420.2001.079004417.x</mixed-citation></ref><ref id="hanspub.29401-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ang, M., Cai, Y., Shahipasand, S., et al. (2016) En Face Optical Coherence Tomography Angiography for Corneal Neovascularisation. British Journal of Ophthalmology, 100, 616-621.  
https://doi.org/10.1136/bjophthalmol-2015-307338</mixed-citation></ref><ref id="hanspub.29401-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">de Carlo, T.E., Rosenblatt, A., Goldstein, M., et al. (2016) Vasculari-zation of Irregular Retinal Pigment Epithelial Detachments in Chronic Central Serous Chorioretinopathy Evaluated with OCT Angi-ography. Ophthalmic Surgery, Lasers and Imaging Retina, 47, 128-133. https://doi.org/10.3928/23258160-20160126-05</mixed-citation></ref><ref id="hanspub.29401-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bonini Filho, M.A., de Carlo, T.E., Ferrara, D., et al. (2015) Association of Choroidal Neovascularization and Central Serous Chorioretinopathy with Optical Coherence Tomography Angiography. JAMA Ophthalmology, 133, 899-906.  
https://doi.org/10.1001/jamaophthalmol.2015.1320</mixed-citation></ref><ref id="hanspub.29401-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Costanzo, E., Cohen, S.Y., Miere, A., et al. (2015) Optical Coherence Tomography Angiography in Central Serous Chorioretinopathy. Journal of Ophthalmology, 2015, 134783.</mixed-citation></ref><ref id="hanspub.29401-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Gao, S.S., Bailey, S.T., et al. (2015) Automated Choroidal Neovascularization Detection Algorithm for Optical Coherence Tomography Angi-ography. Biomedical Optics Express, 6, 3564-3576.  
https://doi.org/10.1364/BOE.6.003564</mixed-citation></ref><ref id="hanspub.29401-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M., Wang, J., Pechauer, A.D., et al. (2015) Advanced Image Processing for Optical Coherence Tomographic Angiography of Macular Diseases. Biomedical Optics Express, 6, 4661-4675. https://doi.org/10.1364/BOE.6.004661</mixed-citation></ref><ref id="hanspub.29401-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Smretschnig, E., Hagen, S., Glittenberg, C., et al. (2016) Intravitreal Anti-Vascular Endothelial Growth Factor Combined with Half-Fluence Photodynamic Therapy for Choroidal Neovascularization in Chronic Central Serous Chorioretinopathy. Eye (London), 30, 805-811. https://doi.org/10.1038/eye.2016.41</mixed-citation></ref><ref id="hanspub.29401-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yan, Y., Wang, T., Cao, J., et al. (2015) Clinical Research on Intravitreal Injection of Bevacizumab in the Treatment of Macula Lutea and Retinal Edema of Ocular Fundus Disease. Pakistan Journal of Pharmaceutical Sciences, 28, 1481-1484.</mixed-citation></ref><ref id="hanspub.29401-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mastropasqua, L., Toto, L., Borrelli, E., et al. (2017) Optical Coherence Tomography Angiography Assessment of Vascular Effects Occurring after Aflibercept Intravitreal Injections in Treatment-Naive Patients with Wet Age-Related Macular Degeneration. Retina, 37, 247-256. https://doi.org/10.1097/IAE.0000000000001145</mixed-citation></ref><ref id="hanspub.29401-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">李燕, 汪亮, 徐晓晨. OCTA评价康柏西普治疗湿性年龄相关性黄斑变性的疗效[J]. 国际眼科杂志, 2018, 18(7): 1305-1309.</mixed-citation></ref></ref-list></back></article>